Research positions Nordic Bioscience’s PRO-C6 as next-generation biomarker
The PRO-C6 biomarker assay has been transferred to Roche Diagnostics for further analysis
Read More
Author: Fleur Jeffries
EMA accepts application for leukaemia drug from Otsuka and Astex
The marketing authorisation application is supported by results from a phase 3 trial for AML
Read More
EMA accepts Mundipharma’s application for candidiasis drug rezafungin
Despite current treatments, the mortality rate for patients with invasive candidiasis remains high
Read More
New study use musical tests for early detection of cognitive decline
Researchers at Tel Aviv University used a portable brain activity-measuring device to detect cognitive decline in older people
Read More
Jazz Pharmaceuticals’ epilepsy drug advances into phase 3 trial
Epidiolex may ease symptoms associated with Doose syndrome, a rarer type of childhood-onset epilepsy
Read More- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
